Lyme Disease and Coinfections Diagnostics
Lyme Disease
CommercialActive (but clinical service suspended)
Key Facts
Indication
Lyme Disease
Phase
Commercial
Status
Active (but clinical service suspended)
Company
About Fry Laboratories
Fry Laboratories is a private, Arizona-based diagnostics company that historically provided specialized testing services for complex conditions like Lyme disease and chronic inflammatory illnesses. Its core technology platform, RIDI™ (Rapid Infectious Disease Identification by Sequencing), uses next-generation DNA sequencing to detect bacteria, fungi, and protists. The company is currently in a transitional state, having halted routine clinical services to focus on R&D and potential partnerships for its sequencing-based diagnostic and antibiotic resistance detection technologies. Leadership includes founder Dr. Stephen E. Fry and CEO Judith Joseph.
View full company profileTherapeutic Areas
Other Lyme Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| VLA15 | Valneva | Phase 3 |
| Lyme Disease Diagnostic | BlueArc Biosciences | Research/Proof-of-Concept |
| Lyme Disease Vaccine | CyanVac | Preclinical |
| Next-Gen Lyme Test | Kephera Diagnostics | Development/Validation |
| Lyme Disease Diagnostic Personalization | Innatoss Laboratories | Research |